United States· US:71288-904_dbc6ea33-ff54-44b2-9ac7-cd76b4cb9c43
Garzulys
A medicinal product containing insulin aspart, registered in United States by Meitheal Pharmaceuticals Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- INSULIN ASPART
- Manufacturer
- Meitheal Pharmaceuticals Inc.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc1171288-904-10
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin aspart in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaDAZPARDAGan & Lee Pharmaceuticals Europe GmbH, Düsseldorf
- United KingdomFiasp 100units/ml solution for injection 10ml vialsNovo Nordisk Ltd
- BelgiumDazparda 100 U/mlGan & Lee Pharmaceuticals Europe
- FinlandDazpardaGan & Lee Pharmaceuticals Europe GmbH
- SwedenDazparda 100 E/ml Injektionsvätska, lösning i förfylld injektionspennaGan & Lee Pharmaceuticals Europe GmbH
- IcelandFiaspNovo Nordisk A/S*
- PolandDazpardaGan & Lee Pharmaceuticals Europe GmbH
- IrelandDazparda 100 units/ml solution for injection in pre-filled penGan & Lee Pharmaceuticals Europe GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Dazparda, Fiasp
- Liechtenstein · Dazparda, Insulin Aspart Sanofi
- Norway · Dazparda, Fiasp
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5c58e0e5-4671-4880-814a-2c33a9bed9af GET /v1/drugs/5c58e0e5-4671-4880-814a-2c33a9bed9af?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS; SUBCUTANEOUS",
"source": "ndc",
"strength": "100",
"substance": "INSULIN ASPART",
"productndc": "71288-904",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "[iU]/mL",
"application_number": "BLA761497",
"marketing_category": "BLA"
}See everything about insulin aspart.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.